COMP <GO>
NHC vs LLY // RSI-14 & 200D SMA MOMENTUM
National HealthCare Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: NHC 4
— LLY 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $212.16 (+0.18%) • MKT CAP: $3.32B
rsi-technicals
35.1
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
rsi-technicals
66.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NHC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NHC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.10% | 32.36% | -22.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.5x | 36.4x | -15.92 | NHC | /valuation <GO> |
| Free Cash Flow Yield | 4.47% | 2.30% | +2.17 | NHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | 40.21% | -31.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 7.90% | 31.90% | -24.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 16.10% | 45.51% | -29.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.16% | 0.49% | +0.67 | NHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.61 | 9.29 | -2.68 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 35.1 | 66.6 | -31.50 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.3x | 26.3x | -2.95 | NHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.32B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NHC REV | LLY REV | NHC GROSS % | LLY GROSS % | NHC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.52B | $65.18B | — | 83.0% | $148.6M | $16.81B |
| FY 2024 | $1.31B | $45.04B | — | 81.3% | $79.7M | $8.82B |
| FY 2023 | $1.14B | $34.12B | — | 79.3% | $111.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NHC // BETA —
LLY // BETA 0.51